

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/130270 A1

(51) International Patent Classification:

C07D 417/12 (2006.01) C07D 495/10 (2006.01)
C07D 417/14 (2006.01) C07D 498/08 (2006.01)
C07D 487/04 (2006.01) C07D 498/10 (2006.01)
C07D 487/10 (2006.01) A61P 1/16 (2006.01)
C07D 491/10 (2006.01) A61K 31/4709 (2006.01)

(21) International Application Number:

PCT/IB2021/061839

(22) International Filing Date:

16 December 2021 (16.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/126,593 17 December 2020 (17.12.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: **BRÅNALT, Jonas**; Astrazeneca AB, SE-151 85 Södertälje (SE). **HOLM, Björn**; Astrazeneca AB, SE-151 85 Södertälje (SE). **JOHANSSON, Maria**; Astrazeneca AB, SE-151 85 Södertälje (SE). **KARLSSON, Olle**; Astrazeneca AB, SE-151 85 Södertälje (SE). **KNERR, Daniel Laurent**; Astrazeneca AB, SE-151 85 Södertälje (SE). **NORDQVIST, Anneli**; Astrazeneca AB, SE-151 85 Södertälje (SE). **SHEPPARD, Robert John**; Astrazeneca AB, SE-151 85 Södertälje (SE). **SWANSON, Marianne**; Astrazeneca AB, SE-151 85 Södertälje (SE). **TOMBERG, Anna**; Astrazeneca AB, SE-151 85 Södertälje (SE).

(74) Agent: **MARK NESS**; c/o Astrazeneca Intellectual Property, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: N-(2-(4-CYANTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES



(57) Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X¹, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

WO 2022/130270 A1